Skip to main content
Clinical Trials/NCT03075566
NCT03075566
Unknown
N/A

Clinical and Biochemical Markers in Coronary Artery Disease

Nadia Bouzidi, PhD1 site in 1 country517 target enrollmentSeptember 2014

Overview

Phase
N/A
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Nadia Bouzidi, PhD
Enrollment
517
Locations
1
Primary Endpoint
Biochemical parameters
Last Updated
9 years ago

Overview

Brief Summary

Atherosclerosis is a chronic inflammatory condition, which is associated by the involvement of several pathological events, and alteration in the serum levels of pro- and anti-inflammatory, and lipid markers.

The investigators evaluated the contribution of serum biomarkers levels to the pathogenesis of coronary artery disease, namely their association with risk factors, clinical presentation, extent and severity of atherosclerotic changes accompanying coronary artery disease.

Registry
clinicaltrials.gov
Start Date
September 2014
End Date
December 2017
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Nadia Bouzidi, PhD
Responsible Party
Sponsor Investigator
Principal Investigator

Nadia Bouzidi, PhD

Bouzidi Nadia, PhD

University of Monastir

Eligibility Criteria

Inclusion Criteria

  • Coronary Artery Disease

Exclusion Criteria

  • Severe respiratory disease
  • Liver disease
  • kidney disease
  • Inflammatory diseases (infections, autoimmune disorders, malignancy).

Outcomes

Primary Outcomes

Biochemical parameters

Time Frame: 1 Days

* Glucose (mmol/l), urae (mmol/l), creatinin (µmol/l), total cholesterol (mmol/l), high density lipoprotein cholesterol, HDL-C (mmol/l), triglycerides (mmol/l), lipoprotein(a) (g/l), apolipoproteins, apo (g/l) were measured only once in each patient at admission, before angiography and in each control group participant using the COBAS INTEGRA 400 chemical analyzer (Roche Diagnostic, Germany). * Troponin I (ng/ml), creatine kinase (CK) (UI/L), creatine kinase MB Isoenzyme (CK-MB)(UI/L), glutamic-oxaloacetic transaminase (ASAT) (UI/L) were measured using the COBAS INTEGRA 400 chemical analyzer (Roche Diagnostic, Germany). Only one measure was performed for each participant regarding all these parameters. * Light density lipoprotein cholesterol, LDL-C (mmol/l) was estimated using the Friedewald equation. Only one measure was performed for each participant. * Values which were out of the confidence range were considered as abnormal values.

Inflammatory markers

Time Frame: 2 Days

* Serum Amyloid A (SAA) (mg/l) was measured using the BN Prospec, Siemens. * High sensitivity C reactive protein, hsCRP (mg/l) was measured using the COBAS INTEGRA 400 chemical analyzer (Roche Diagnostic, Germany). * Activin A (pg/ml) was quantified at 450nm using a commercially available ELISA kit (AbFrontier, Young In Frontier Co., Ltd, Korea). Only one measure was performed for each participant. * Interleukin-6 (pg/ml) was measured using a Cobas E601 analyzer (Roche Diagnostics, Germany). Only one measure was performed for each participant. * Values which were out of the confidence range were considered as abnormal values.

Study Sites (1)

Loading locations...

Similar Trials